What The Global Pharmaceutical Industry Is Planning In 2010-2011: Procurement, Investment & Industry Trends Outlook

Table of Contents

Related Reports

50 Results found for "Related Reports"

Report Title	Report Type	Country	Published	Price
Russia Clinical Trial Market Opportunity Analysis	Market Research	Russia	24 May 2013	£530.20
The Russia clinical trials market is suggested to have reached a value of around $200 million at the end of 2012, and is forecast to grow to a total of $300 million by 2016. The industry is expecte...			More Info Add to Wishlist
Argentina Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Argentina	22 May 2013	£858.26
High inflation has undermined foreign drugmakers' profitability in Argentina's pharmaceutical market. The potential currency devaluation will further erode the returns of foreign investment.<br ...			More Info Add to Wishlist
Algeria Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Algeria	22 May 2013	£858.26
Algerian authorities appear committed to healthcare development programme, the 2010-2014 tranche of which envisages the construction of more than 150 new hospitals and numerous other facilities. This ...			More Info Add to Wishlist
Zambia Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Zambia	22 May 2013	£858.26
Zambia has a strong economy thanks to its relative political stability and copper mining industry, but there are considerable gaps in its provision of healthcare services. With many specialist healthc...			More Info Add to Wishlist
Hong Kong Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Hong Kong	22 May 2013	£858.26
Hong Kong's attractiveness as a pharmaceutical market hinges largely on its ageing and affluent demographics, its proximity to China as well as the stable political and economic environment.<br ...			More Info Add to Wishlist
New Zealand Pharmaceuticals and Healthcare Report Q3 2013	Market Research	New Zealand	22 May 2013	£858.26
Low growth potential in New Zealand's pharmaceutical market will attract risk-averse investors. However, we note that regulatory delays in funding new medicines will hinder patients' access to pharmac...			More Info Add to Wishlist
Taiwan Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Taiwan	22 May 2013	£858.26
Taiwan will continue to represent a modestly attractive proposition for drug manufactures. Our view is based on factors such as the maturity of its pharmaceutical market, government encouragement of g...			More Info Add to Wishlist
Wound Care in Hong Kong, China	Market Research	Hong Kong	17 May 2013	£600.00
Wound care in 2012 had a stronger and steady current value growth with 2% due to a wider range and more innovative products offered in the market. There were more innovative packaging changes covering...			More Info Add to Wishlist
Analgesics in Hong Kong, China	Market Research	Hong Kong	17 May 2013	£600.00
Mainland Chinese visitors and traders prefer to buy analgesics in bulk in Hong Kong since there is a high tax in mainland China. The depreciation of the Hong Kong dollar also spearheaded more spending...			More Info Add to Wishlist
China Health Food Industry Report, 2013	Market Research	China	17 May 2013	£1,400.00
Health food arose in China in 1980s; after three decades of development, China health food industry has formed with the value of RMB100 billion. In 2012, the sales revenue of the health food industry ...			More Info Add to Wishlist
Healthcare Distribution and Services Industry in the US - PEST Framework Analysis	Market Research	United States	16 May 2013	£132.55
The Healthcare Distributors and Services industry includes all distributors and wholesalers of health care products, plus dialysis centers and lab testing services. Wholesale drug distributors include...			More Info Add to Wishlist
Wound Care in Turkey	Market Research	Turkey	15 May 2013	£600.00
Wound care in Turkey increased in value by 1% in 2012, a rate of growth which was commensurate with the 1% current value CAGR recorded over the entire review period. This low value growth was the resu...			More Info Add to Wishlist
Analgesics in Turkey	Market Research	Turkey	15 May 2013	£600.00
Analgesics in Turkey remained a small OTC category at the end of the review period as only a limited range of topical analgesics/anaesthetic were able to be sold in the country without a prescription....			More Info Add to Wishlist
Healthcare IT Market: Global Forecasts to 2017	Market Research	Global	15 May 2013	£3,081.78
The global healthcare IT market is suggested to have reached a value of around $40.4 billion by the end of 2012, and is forecast to grow to a total of $56.7 billion by 2017. This would suggest a CA...			More Info Add to Wishlist
Cote d'Ivoire Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Ivory Coast	15 May 2013	£858.26
The risks of investing in Côte d'Ivoire's pharmaceutical and healthcare industry are numerous. Politically, the country is in a fragile state, with concerns over security commonplace.Econo...			More Info Add to Wishlist
Croatia Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Croatia	15 May 2013	£858.26
Croatia's entrance into the EU will accelerate its economic liberalisation and the development of the country's private sector. It is also likely to bring about an influx of EU funding in modernising ...			More Info Add to Wishlist
Japan Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Japan	15 May 2013	£858.26
Japan remains the most attractive market in the Asia Pacific, due to the ageing and affluent population and strong regulatory conditions. In particular, we highlight that the slowing economy poses opp...			More Info Add to Wishlist
Pakistan Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Pakistan	15 May 2013	£858.26
Increased longevity in developed markets translates into an increased demand for aged care healthcare services and medicines. However, in emerging markets such as Pakistan, despite increased life expe...			More Info Add to Wishlist
Sudan and South Sudan Pharmaceuticals and Healthcare Report Q3 2013	Market Research	Sudan	15 May 2013	£858.26
Sudan will remain one of the least attractive countries in the Middle East/Africa region due to low pharmaceutical and healthcare expenditure. The government's low commitment to healthcare, combined w...			More Info Add to Wishlist
MediFocus: Medical Devices for the Treatment of Obesity	Market Research	Global	15 May 2013	£2,647.68
The obesity medical device market is expected to experience significant change in the near future, as new products come to market, older products see a decline in sales, physician adoption increases w...			More Info Add to Wishlist

1325.5

Select License Type

£1,325.50	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£2,650.99	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£3,976.49	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,325.50	Add to Wishlist
Change Currency	GBP EURO USD

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	29 January 2010
Number of Pages	132
Report Delivery	Email
Delivery Lead Time	-
Publisher	ICD Research

Chapter 1: Executive Summary
Chapter 2: Introduction
Heading: Profile Of Survey Respondents
Chapter 3: Industry Dynamics
Heading: Revenue Growth Expectations In The Pharmaceutical Industry
Heading: Future Developments In Competitive Structure In The Industry
Heading: Merger And Acquisition Activity Predictions
Chapter 4: Pharmaceutical Market Growth Outlook
Heading: Regional Growth Forecasts In The Pharmaceutical Industry By Country
Heading: Market Growth Forecasts By Industry Sector
Chapter 5: Threats And Opportunities For The Pharmaceutical Industry
Heading: Leading Business Concerns For The Period 2010-2011
Heading: Key Actions To Overcome Business Threats: Cost Management
Heading: Key Actions To Overcome Business Threats: Driving Sales
Heading: Key Supplier Actions To Maintain And Win Buyer Business
Chapter 6: Pharmaceutical Industry Buyer Spend Activity
Heading: Annual Procurement Budgets: Pharmaceutical Industry
Heading: Procurement Cost Saving Targets In The Pharmaceutical Industry
Heading: Planned Change In Procurement Spend
Heading: Planned Change In Procurement Spend By Product And Service Category
Chapter 7: Procurement Behaviors And Strategies
Heading: Critical Success Factors For Supplier Selection
Heading: Expected Future Changes In Procurement Objectives
Heading: Areas Of Future Value Creation In Procurement Strategy
Heading: Mitigating Supplier Failure And Maintaining Business Continuity
Heading: Planning Against Business Supply Contingencies
Chapter 8: Appendix

Table 1: Count Of Global Pharmaceutical Industry Survey Respondents By Company Type (Number Of Respondents), 2010 Industry Survey
Table 2: Buyer Respondents By Job Role (% Buyer Respondents), Global Pharmaceutical Industry, 2010
Table 3: Buyer Respondents By Organization's Global Turnover (% Buyer Respondents), Global Pharmaceutical Industry, 2010
Table 4: Buyer Respondents By Organization's Total Employee Size (% Buyer Respondents), Global Pharmaceutical Industry, 2010
Table 5: Buyer Respondents By Region (% Buyer Respondents), Global Pharmaceutical Industry, 2010
Table 6: Supplier Respondents By Job Role (% Supplier Respondents), Global Pharmaceutical Industry, 2010
Table 7: Supplier Respondents By Organization's Global Turnover (% Supplier Respondents), Global Pharmaceutical Industry, 2010
Table 8: Supplier Respondents By Organization's Total Employee Size (% Supplier Respondents), Global Pharmaceutical Industry, 2010
Table 9: Supplier Respondents By Region (% Supplier Respondents), Global Pharmaceutical Industry, 2010
Table 10: Company Revenue Growth Optimism Trend By Global Pharmaceutical Industry Company Type: Pharmaceutical Manufacturers, CRO / CMO Companies, Pharmaceutical Industry Suppliers, Pharmaceutical Industry Suppliers (% All Respondents), 2009-2010
Table 11: Company Revenue Growth Optimism Trend In The Global Pharmaceutical Industry By Region: North America, Europe, Asia-Pacific, Rest Of The World (% All Respondents), 2009-2010
Table 12: Company Revenue Growth Optimism In The Global Pharmaceutical Industry By Turnover (% All Respondents), 2010
Table 13: Pharmaceutical Manufacturer Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% Pharmaceutical Manufacturer Respondents), 2010
Table 14: CRO / CMO Company Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% CRO / CMO Company Respondents), 2010
Table 15: Pharmaceutical Industry Supplier Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% Pharmaceutical Industry Supplier Respondents), 2010
Table 16: Pharmaceutical Manufacturer Predictions Of The Fastest And Slowest Growing Industry Sectors (% Pharmaceutical Manufacturer Respondents), 2010
Table 17: CRO / CMO Company Predictions Of The Fastest And Slowest Growing Industry Sectors (% CRO / CMO Company Respondents), 2010
Table 18: Pharmaceutical Industry Supplier Predictions Of The Fastest And Slowest Growing Industry Sectors (% Pharmaceutical Industry Supplier Respondents), 2010
Table 19: Global Pharmaceutical Industry Predictions Of The Fastest And Slowest Growing Industry Sectors By Region: North America, Europe, Asia-Pacific, Rest Of The World (% 'Very Strong Growth' And 'Strong Growth' Combined, All Respondents), 2010
Table 20: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. Vs. Pharmaceutical Industry Supplier Vs.: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers (% All Respondents), 2010
Table 21: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers By Region: North America, Europe, Asia-Pacific, Rest Of The World (% All Respondents), 2010
Table 22: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers By Company Turnover (% All Respondents), 2010
Table 23: Most Important Actions Being Implemented To Facilitate Cost Containment In 2010-2011 In The Global Pharmaceutical Industry (% All Respondents), 2010
Table 24: Most Important Actions Being Implemented To Facilitate Cost Containment In 2010-2011 In The Global Pharmaceutical Industry – Senior Level Responses Only (% Ceo/Md/Board Level Respondents), 2010
Table 25: Most Important Actions Being Implemented To Facilitate Cost Containment In 2010-2011 In The Global Pharmaceutical Industry: Buyer Vs. Supplier Comparison (% All Respondents), 2010
Table 26: Most Important Actions Being Implemented For Driving Sales To Overcome Present Business Challenges In 2010-2011 In The Global Pharmaceutical Industry (% All Respondents), 2010
Table 27: Most Important Actions Being Implemented For Driving Sales To Overcome Present Business Challenges In 2010-2011 In The Global Pharmaceutical Industry – Senior Level Responses Only (% Ceo/Md/Board Level Respondents), 2010
Table 28: Most Important Actions Being Implemented For Driving Sales To Overcome Present Business Challenges In 2010-2011 In The Global Pharmaceutical Industry: Buyer Vs. Supplier Comparison (% All Respondents), 2010
Table 29: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Supplier Responses Vs. All Buyer Responses (% All Respondents), 2010
Table 30: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% Buyer Respondents), 2010
Table 31: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of Buyer Respondents By Company Turnover (% Buyer Respondents), 2010
Table 32: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of All Buyer Respondents By Procurement Budget (% Buyer Respondents), 2010
Table 33: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of All Buyer Respondents By Region (% Buyer Respondents), 2010
Table 34: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of All Buyer Respondents By Purchasing Decision Seniority (% Buyer Respondents With Purchasing Decision Influence), 2010
Table 35: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Table 36: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Company Turnover (% All Buyer Respondents), 2010
Table 37: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Region (% All Buyer Respondents), 2010
Table 38: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Region (% All Buyer Respondents), 2009
Table 39: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Table 40: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Company Turnover: (% All Buyer Respondents), 2010
Table 41: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Region: (% All Buyer Respondents), 2010
Table 42: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Leading Business Concern (Cost Containment): (% All Buyer Respondents), 2010
Table 43: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents) 2010 (With Comparison To 2009 Expectations)
Table 44: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months By Company Turnover (% All Buyer Respondents), 2010 (With Comparison To 2009 Expectations)
Table 45: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months By Region (% All Buyer Respondents), 2010
Table 46: Proportion Of Industry Players Planning to Increase or Decrease Planned Spend Level in 2010: Global Pharmaceutical Industry Comparison Vs. Other Industries (% All Respondents), 2010
Table 47: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Pharmaceutical Manufacturer - Expected Increase Or Decrease Over The Next 12 Months (% Pharmaceutical Manufacturer Respondents), 2010
Table 48: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: CRO / CMO Company - Expected Increase Or Decrease Over The Next 12 Months (% CRO / CMO Company Respondents), 2010
Table 49: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Buyer Vs. Supplier Comparison (% All Respondents), Global, 2010
Table 50: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Pharmaceutical Manufacturer Vs. CRO / CMO Company Comparison (% All Buyer Respondents), Global, 2010
Table 51: Pharmaceutical Manufacturer Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following Statement (% Pharmaceutical Manufacturer Respondents), 2010
Table 52: CRO / CMO Company Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following Statement (% CRO / CMO Company Respondents), 2010
Table 53: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Table 54: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: All Buyers By Company Turnover (% All Buyer Respondents), 2010
Table 55: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: All Buyers By Purchasing Decision Seniority (% All Buyer Respondents Purchasing Decision Influence), 2010
Table 56: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: All Buyers By Region (% All Buyer Respondents), 2010
Table 57: Pharmaceutical Manufacturer Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following 3 Statements (% Pharmaceutical Manufacturer Respondents), 2010
Table 58: CRO / CMO Company Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following 3 Statements (% CRO / CMO Company Respondents), 2010
Table 59: Critical Strategies Adopted By Buyers To Ensure Business Continuity In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Table 60: Critical Strategies Adopted By Buyers To Ensure Business Continuity In The Global Pharmaceutical Industry By Company Turnover: (% All Buyer Respondents), 2010
Table 61: Pharmaceutical Manufacturer Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following Statement (% Pharmaceutical Manufacturer Respondents), 2010
Table 62: CRO / CMO Company Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following Statement (% CRO / CMO Company Respondents), 2010
Table 63: Actions Undertaken By Buyers To Survive Product/Service Inflation And/Or Supply Shortages In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Table 64: Actions Undertaken By Buyers To Survive Product/Service Inflation And/Or Supply Shortages In The Global Pharmaceutical Industry By Company Turnover: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Table 65: Full Survey Results - Closed Questions

Figure 1: Company Revenue Growth Optimism Trend In The Global Pharmaceutical Industry (% All Respondents), 2009-2010
Figure 2: Company Revenue Growth Optimism Trend By Global Pharmaceutical Industry Company Type: Pharmaceutical Manufacturers, CRO / CMO Companies, Pharmaceutical Industry Suppliers, Pharmaceutical Industry Suppliers (% All Respondents), 2009-2010
Figure 3: Company Revenue Growth Optimism Trend In The Global Pharmaceutical Industry By Region: North America, Europe, Asia-Pacific, Rest Of The World (% All Respondents), 2009-2010
Figure 4: Company Revenue Growth Optimism In The Global Pharmaceutical Industry Over The Next 12 Months: Cross-Industry Comparison (% All Respondents), 2010
Figure 5: Key Expected Changes In Business Structure In The Global Pharmaceutical Companies Industry (% Pharmaceutical Manufacturer Respondents), 2010
Figure 6: Key Expected Changes In Business Structure In The Global CRO / CMO Company Industry (% CRO / CMO Company Respondents), 2010
Figure 7: Key Expected Changes In Business Structure In The Global Pharmaceutical Industry Supplier Industry (% Pharmaceutical Industry Supplier Respondents), 2010
Figure 8: Merger And Acquisition Activity Expectations Over The Next 12 Months In The Global Pharmaceutical Manufacturer Industry (% Pharmaceutical Manufacturer Industry Respondents), 2009-2010 Trend Forecast
Figure 9: Merger And Acquisition Activity Expectations Over The Next 12 Months In The Global CRO / CMO Company Industry: (% CRO / CMO Company Industry Respondents), 2009-2010 Trend Forecast
Figure 10: Merger And Acquisition Activity Expectations Over The Next 12 Months In The Global Pharmaceutical Industry Supplier Industry (% Pharmaceutical Industry Supplier Industry Respondents), 2009-2010 Trend Forecast
Figure 11: Pharmaceutical Manufacturer Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% Pharmaceutical Manufacturer Respondents), 2010
Figure 12: CRO / CMO Company Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% CRO / CMO Company Respondents), 2010
Figure 13: Pharmaceutical Industry Supplier Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% Pharmaceutical Industry Supplier Respondents), 2010
Figure 14: Pharmaceutical Manufacturer Predictions Of The Fastest And Slowest Growing Industry Sectors (% Pharmaceutical Manufacturer Respondents), 2010
Figure 15: CRO / CMO Company Predictions Of The Fastest And Slowest Growing Industry Sectors (% CRO / CMO Company Respondents), 2010
Figure 16: Pharmaceutical Industry Supplier Predictions Of The Fastest And Slowest Growing Industry Sectors (% Pharmaceutical Industry Supplier Respondents), 2010
Figure 17: Global Pharmaceutical Industry Predictions Of The Fastest And Slowest Growing Industry Sectors By Region: North America, Europe, Asia-Pacific, Rest Of The World (% 'Very Strong Growth' And 'Strong Growth' Combined, All Respondents), 2010
Figure 18: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers (% All Respondents), 2010
Figure 19: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. Vs. Pharmaceutical Industry Supplier Vs.: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers (% All Respondents), 2010
Figure 20: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Supplier Responses Vs. All Buyer Responses (% All Respondents), 2010
Figure 21: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% Buyer Respondents), 2010
Figure 22: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of All Buyer Respondents By Region (% Buyer Respondents), 2010
Figure 23: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Figure 24: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2009
Figure 25: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Company Turnover (% All Buyer Respondents), 2010
Figure 26: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Company Turnover (% All Buyer Respondents), 2009
Figure 27: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Region (% All Buyer Respondents), 2010
Figure 28: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Figure 29: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Region: (% All Buyer Respondents), 2010
Figure 30: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Leading Business Concern (Cost Containment): (% All Buyer Respondents), 2010
Figure 31: Average Identified Procurement Savings Target In The Global Pharmaceutical Industry Over The Next 12 Months: Global Pharmaceutical Industry Vs. Other Industries (% All Respondents), 2010
Figure 32: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents) 2010 (With Comparison To 2009 Expectations)
Figure 33: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months By Region (% All Buyer Respondents), 2010 (With Comparison To 2009 Expectations)
Figure 34: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Pharmaceutical Manufacturer - Expected Increase Or Decrease Over The Next 12 Months (% Pharmaceutical Manufacturer Respondents), 2010
Figure 35: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: CRO / CMO Company - Expected Increase Or Decrease Over The Next 12 Months (% CRO / CMO Company Respondents), 2010
Figure 36: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Expected Increase Over The Next 12 Months Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Figure 37: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Expected Increase Over The Next 12 Months Among All Buyers By Company Turnover (% All Buyer Respondents), 2010
Figure 38: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Expected Increase Over The Next 12 Months Among All Buyers By Region (% All Buyer Respondents), 2010
Figure 39: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Difference In Views, Buyers Vs. Suppliers (Net Difference In Ranking), Global, 2010
Figure 40: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Buyer Vs. Supplier Comparison (% All Respondents), Global, 2010
Figure 41: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Pharmaceutical Manufacturer Vs. CRO / CMO Company Comparison (% All Buyer Respondents), Global, 2010
Figure 42: Expected Future Changes In Procurement Objectives In The Global Pharmaceutical Industry (% All Buyer Respondents), 2010
Figure 43: Expected Future Changes In Procurement Objectives In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Figure 44: Expected Future Changes In Procurement Objectives In The Global Pharmaceutical Industry By Company Turnover (% All Buyer Respondents), 2010
Figure 45: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business (% All Buyer Respondents), 2010
Figure 46: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Figure 47: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: All Buyers By Region (% All Buyer Respondents), 2010
Figure 48: Critical Strategies Adopted By Buyers To Ensure Business Continuity In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Figure 49: Critical Strategies Adopted By Buyers To Ensure Business Continuity In The Global Pharmaceutical Industry By Region: (% All Buyer Respondents), 2010
Figure 50: Actions Undertaken By Buyers To Survive Product/Service Inflation And/Or Supply Shortages In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Figure 51: Actions Undertaken By Buyers To Survive Product/Service Inflation And/Or Supply Shortages In The Global Pharmaceutical Industry By Region: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£1,325.50	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£2,650.99	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£3,976.49	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,325.50	Add to Wishlist
Change Currency	GBP EURO USD

Change Currency

GBP

EURO

USD

Healthcare and Medical Company Profiles

Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

What The Global Pharmaceutical Industry Is Planning In 2010-2011: Procurement, Investment & Industry Trends Outlook

50 Results found for "Related Reports"

Select License Type

Table of Contents

Speak to an Advisor

Select License Type

Change Currency

Healthcare and Medical Company Profiles

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In